MARKETS / NYSE / TEVA

NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Teva Pharmaceutical Industries Ltd. TEVA

17 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$17.3B

▲ 4.3% YoY

Net income

$1.4B

Free cash flow

$1.1B

▲ 53.3% YoY

In brief

What this company does

Teva Pharmaceutical Industries Limited innovates in the fields of neuroscience and immunology while providing complex generic medicines, biosimilars and pharmacy brands worldwide. It operates worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets, and its global network comprises approximately 34,000 employees across 57 markets. It operates its business through three segments: United States, Europe and International Markets. Its Europe segment includes the European Union, the United Kingdom and certain other European countries. Its International Markets segment covers a substantial portion of the global pharmaceutical industry, including more than 35 countries. In 2025, it produced approximately 66 billion tablets and capsules, and approximately 600 million sterile units. Teva was incorporated in Israel on February 13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901.

Written from the business description in TEVA PHARMACEUTICAL INDUSTRIES LIMITED's annual report to the U.S. Securities and Exchange Commission, filed 3 February 2026. Every sentence was checked against that document before publication.

Growth

USD 17.3B

Revenue, FY2025 · full 17-year series below

Revenue $B Net income $B

FY2025 · Revenue 17.3 · Net income 1.4

Compound annual growth

Revenue

+5.0%

+0.7%

+0.5%

Net income

−5.6%

Returned to shareholders

−61.9%

−29.3%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +0.7% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

8 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 12.5% · Net 8.2%

ROE

FY2025 · ROE 21.2%

Gross margin51.8%

Operating margin12.5%

Net margin8.2%

Return on assets3.5%

EBITDAUSD 2.6B

Each USD of equity produced 21 cents of profit this year.

Cash & shareholders

—

returned in FY2025 · dividends + net buybacks

Free cash flow $B

FY2025 · FCF 1.1

Net buybacks $B Dividends $B

FY2018 · Dividends 0.0 · Net buybacks —

Total assetsUSD 40.7B

EquityUSD 7.9B

CashUSD 3.6B

Gross debtUSD 1.8B

Net debtUSD -1.8B

Current ratio1.04×

The company holds more cash than debt.

The 17-year record

17 fiscal years

Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2013	2012	2011	2010	2009	2008	2007
Revenue $B	17.3	16.5	15.8	14.9	15.9	16.7	16.9	18.3	21.9	21.9	20.3	20.3	18.3	16.1	16.1	11.1	9.4
Operating income $B	2.2	−0.3	0.4	−2.2	1.7	−3.6	−0.4	−1.6	−17.5	2.2	1.6	2.2	3.1	3.9	2.4	1.1	2.4
EBITDA $B	2.6	0.2	1.0	−1.6	2.2	−3.0	0.2	−1.0	−16.9	2.7	2.1	2.6	3.5	4.3	2.8	1.5	·
Income tax $B	−0.2	0.7	−0.0	−0.6	0.2	−0.2	−0.3	−0.2	−1.9	0.5	−0.0	−0.1	0.1	0.3	0.2	0.2	0.4
Net income $B	1.4	−1.6	−0.6	−2.4	0.4	−4.0	−1.0	−2.1	−16.3	0.3	1.3	2.0	2.8	3.3	2.0	0.6	1.9
Free cash flow $B	1.1	0.7	0.8	1.0	0.2	0.6	0.2	1.8	1.4	3.0	2.2	3.5	3.1	3.4	2.7	2.5	1.3
EPS, diluted $	1.21	−1.45	−0.50	−2.20	0.38	−3.64	−0.91	−2.35	−16.26	0.07	1.49	2.25	3.09	3.67	2.23	0.75	2.36
Dividend / sh $	·	·	·	·	·	·	0.00	0.00	0.85	1.36	1.28	1.03	0.89	0.74	0.61	0.50	·
Payout %	·	·	·	·	·	·	·	−1	−6	396	86	44	29	20	26	64	16
ROE %	21.2	−25.5	−7.3	−27.1	4.1	−33.3	−7.0	−13.4	−93.7	·	5.6	8.7	12.5	16.2	11.2	3.7	·
Shares out B	·	·	·	·	·	·	·	·	·	·	·	·	·	0.94	0.92	0.89	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 81 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 14 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityPharmaceutical Preparations

Listed onNYSE

Incorporated inoutside the United States — SEC code L3

Fiscal year endsDecember 31

Data on record since2007